Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02745769
Title A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

mantle cell lymphoma

colorectal cancer

Therapies

Merestinib + Ramucirumab

Abemaciclib + Ramucirumab

Age Groups: adult
Covered Countries USA | FRA

Facility Status City State Zip Country Details
UAB Comprehensive Cancer Center Birmingham Alabama 35249 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Lyon 69373 France Details
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Marseille 13385 France Details
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. London SE1 9RT United Kingdom Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field